scispace - formally typeset
X

Xin Guan

Researcher at Peking Union Medical College

Publications -  15
Citations -  236

Xin Guan is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Stem cell & CD34. The author has an hindex of 8, co-authored 15 publications receiving 163 citations.

Papers
More filters
Journal ArticleDOI

Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice

TL;DR: The polymer encapsulation of the monoclonal antibody rituximab and the ligand-mediated targeting of metastases in the central nervous system significantly improve antitumour efficacy in mouse models of metastatic non-Hodgkin lymphoma.
Journal ArticleDOI

Large-Scale Ex Vivo Generation of Human Red Blood Cells from Cord Blood CD34+ Cells

TL;DR: It is reported that functional human erythrocytes can be efficiently produced from cord blood (CB) CD34+ cells using a bottle turning device culture system and suggested that the ex vivo‐generated ery Throcytes could be an alternative blood source for traditional transfusion products in the clinic.
Journal ArticleDOI

A small-molecule/cytokine combination enhances hematopoietic stem cell proliferation via inhibition of cell differentiation

TL;DR: An optimal small-molecule/cytokine combination for the enhancement of HSC expansion via inhibition of differentiation is developed and indicates promising application for preparation of both the HSCs and the mature, functional hematopoietic cells for clinical transplantation.
Journal ArticleDOI

An effective ex-vivo approach for inducing endothelial progenitor cells from umbilical cord blood CD34 + cells

TL;DR: An approach for the generation of cord blood-derived EPCs/ECs on a large scale was developed, characterized them phenotypically, and demonstrated their in-vivo functional capacity.
Journal ArticleDOI

Safety and Efficacy of Megakaryocytes Induced from Hematopoietic Stem Cells in Murine and Nonhuman Primate Models.

TL;DR: The development of an efficient two‐stage culture system that is free of stroma, animal components, and genetic manipulations for the production of functional megakaryocytes from hematopoietic stem cells is reported, suggesting that large‐scale induction of functionalmegakaryocytic cells is applicable for treating thrombocytopenic blood diseases in the clinic.